Paradigm Health
9 known investors
Paradigm Health operates a clinical research platform that combines a global provider network with AI-powered software to make clinical trials more accessible and efficient for patients, researchers, and study sponsors. The company implements its infrastructure at healthcare provider organizations to reduce barriers to trial participation.
Also known as Paradigm · Paradigm Health, Inc.
Founders & leadership
Investors · 9
.png)
Also in the syndicate · 4
Company profile
researched Aug 2026Paradigm Health is a Columbus, Ohio and New York-based technology company that operates a clinical research platform designed to embed trials into routine patient care. The company combines an AI-powered software layer with a network of healthcare provider organizations, implementing a single infrastructure at provider sites intended to reduce administrative barriers for research staff while widening patient access to trials. Its stated mission is to create equitable access to clinical trials for any patient, anywhere, with emphasis on community and rural settings that historically have less access than academic medical centers.
The platform automates patient matching and site feasibility, and the company reports that participating health systems accrued to trials four times faster. Paradigm Health supports Phase I–III oncology trials for 15 of the top 20 global pharmaceutical companies and has begun expanding commercially into neuroscience, cardiovascular disease, metabolic conditions and other therapeutic areas. It also launched a Trial Design Service that allows sponsors to design and execute interventional and pragmatic trials embedded into routine care. Following the December 2025 acquisition of Flatiron Health's Clinical Research Business, the company describes itself as operating the largest oncology research network in the United States, and the combined network adds capacity for Phase IV trials built into routine care.
Paradigm Health was incubated by ARCH Venture Partners in 2021 and is backed by healthcare and life sciences investors. Its leadership team is drawn from the CRO, health data and healthcare operations sectors, and its board and advisory board include investors and former pharmaceutical, regulatory and health-system executives.
Founding story
The company was incubated in 2021 by ARCH Venture Partners to address inequities in patient access to clinical research. Kent Thoelke, a 30-year clinical research industry veteran who previously served as Chief Innovation Officer at ICON plc following its acquisition of PRA Health Sciences (where he was Chief Scientific Officer), is founder and CEO. Robert Nelsen of ARCH Venture Partners is described as co-founder and board chair.
Business model
Paradigm Health provides a combined technology-and-services model that spans the clinical trial journey, serving two customer sides: biopharmaceutical sponsors who need faster, more efficient trials, and healthcare provider organizations that want to offer trials to their patients. Its infrastructure is implemented directly at provider organizations, and it additionally offers a Trial Design Service for sponsors designing interventional and pragmatic trials embedded in routine care.
Traction
As of December 2025 the platform spanned 45 U.S. states and 166 healthcare provider organizations with 2,100 care locations, including 123 community oncology practices and 43 health systems and academic medical centers (23 of them NCI-Designated Cancer Centers), covering 70% of the U.S. cancer population. It supports Phase I–III oncology trials for 15 of the top 20 global pharmaceutical companies. Reported customer outcomes include Highlands Oncology increasing clinical trial participation 45% over two years, Altru Health System raising enrollment from 4% to 11% of its oncology population with pre-screening rising from 10,200 to over 21,200 annual cancer patient visits, and Ochsner Health increasing patient screening capacity by 41%. Fierce Biotech reported the combined network with Flatiron sites is expected to reach roughly 2.4 million U.S. patients.
Latest developments
On December 4, 2025 Paradigm Health announced a $78 million Series B and the acquisition of Flatiron Health's Clinical Research Business plus a long-term strategic partnership with Flatiron, financial terms undisclosed. The company recently launched a Trial Design Service. Company-listed news includes a June 30, 2026 response to the FDA's Real-Time Clinical Trials Initiative RFI, in which it describes itself as the sole technology provider operationalizing the initiative, and an August 12, 2026 announcement with Ochsner Health to expand clinical trial access across the Gulf South.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Paradigm Health describes itself as operating the largest oncology research network in the United States following the Flatiron Health clinical research business acquisition, with a network placing 70% of the U.S. cancer population within easy access to a trial site. It positions itself as an AI-native alternative to conventional clinical research infrastructure concentrated in academic centers.
The company pairs a broad provider network with AI-driven automation of patient matching and site feasibility, orienting trials around routine patient care rather than dedicated research centers. Coverage cites its national network scale, trial-design capabilities and reported speed gains (four times faster accrual) as distinguishing features.
Technology
An AI-native, AI-enabled research platform that automates patient matching and site feasibility, integrating with healthcare provider organizations. The company has applied large language models to clinical trial matching; a case study reports its use of GPT-4 for patient screening being 10% more accurate than state-of-the-art machine learning models while requiring 90% less expert clinician time, work highlighted by OpenAI.
Go-to-market
The company sells to global biopharmaceutical sponsors and to health systems, community oncology practices and academic medical centers, integrating its platform into provider workflows. It also grows through partnerships with health systems and regional partners (e.g., Ochsner Health in the Gulf South, Sheba Medical Center and ARC Innovation in Israel, Fujitsu in Japan) and through acquisition, notably Flatiron Health's clinical research business. Published case studies with Highlands Oncology, Altru Health System and Ochsner Health are used to demonstrate outcomes.
Biopharmaceutical study sponsors (including 15 of the top 20 global pharmaceutical companies), health systems, academic medical centers, NCI-Designated Cancer Centers and community oncology practices, and ultimately patients seeking access to trials, particularly in community and rural settings.
Geography
Headquartered at 175 S. 3rd St, Suite 1000, Columbus, OH 43215, with a New York presence cited in press releases. Its U.S. network spans 45 states and 2,100 care locations. Internationally, the company describes a global provider network from North America to East Asia, with collaborations in Israel (Sheba Medical Center and ARC Innovation) and Japan (Fujitsu).
History
ARCH Venture Partners incubated the company in 2021. Paradigm Health subsequently emerged from stealth and announced a Series A of more than $200 million co-led by ARCH Venture Partners and General Catalyst with F-Prime, GV, Lux Capital, Mubadala, the American Cancer Society's BrightEdge Fund and others. It then announced a strategic partnership with Bristol-Myers Squibb and a partnership with Sheba Medical Center and ARC Innovation in Israel. On December 4, 2025 the company announced an oversubscribed $78 million Series B led by ARCH Venture Partners and the acquisition of Flatiron Health's Clinical Research Business alongside a long-term partnership with Flatiron. In 2026 it announced an expanded clinical trial access partnership with Ochsner Health and a response to the FDA's Real-Time Clinical Trials Initiative RFI.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 2
by search overlapCompanies competing with Paradigm Health for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 9
launches, deals, and filingsCompany submitted a response to the FDA's Real-Time Clinical Trials (RTCT) Initiative request for information, informed by biopharma sponsors and providers; it describes itself as the sole technology provider operationalizing the initiative.
Paradigm Health acquired Flatiron Health's clinical research business unit and entered a long-term partnership with Flatiron combining Flatiron's clinical research solutions with Paradigm's end-to-end technology platform. Financial terms were not disclosed. The combined network is described as the largest oncology research network in the United States, adding more than 25 academic medical centers and health systems and access to nearly 100 local oncology practices, reaching about 2.4 million U.S. patients and adding Phase IV trial capacity.
Oversubscribed $78M Series B led by ARCH Venture Partners with new investor DFJ Growth and existing investors F-Prime, General Catalyst, GV, Lux Capital, Mubadala Capital and the American Cancer Society's BrightEdge Fund; several investors took super pro-rata positions. Proceeds to fund expansion in the U.S. and globally.
$78M source ↗
Paradigm Health launched a Trial Design Service enabling sponsors to design and execute interventional and pragmatic trials embedded directly into routine care.
Collaboration to reduce administrative burden of clinical trial participation for Japanese hospitals, expand patient access, and give global pharmaceutical companies a streamlined path to hospitals in Japan.
ARCH Venture Partners incubated the company in 2021 to address inequities of patient access to clinical research; the company later emerged from stealth.
Collaboration to deploy an AI-driven clinical trial platform at Sheba Medical Center and scale it to research sites throughout Israel.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Paradigm Healthparadigmhealth.ai · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Paradigm Health do?
- AI-native clinical trial platform embedding oncology and other research into routine care at health systems and community practices.
- Who founded Paradigm Health?
- Paradigm Health was founded by Kent Thoelke.
- Who are Paradigm Health's investors?
- Paradigm Health's investors include ARCH Venture Partners, General Catalyst, GV (Google Ventures), Lux Capital, JobsOhio Ventures.